Loading...

Valerio Therapeutics SA

ALVIO.PAEURONEXT
Healthcare
Biotechnology
0.06
0.003(5.15%)

Valerio Therapeutics SA (ALVIO.PA) Stock Competitors & Peer Comparison

See (ALVIO.PA) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
ALVIO.PA€0.06+5.15%8.4M-0.34-€0.16N/A
UCB.BR€181.00+1.17%33.9B32.57€5.47+0.67%
ARGX.BR€512.20+3.68%30.8B36.08€13.97N/A
TUB.BR€144.00+0.42%6.3B70.50€2.02+0.63%
ABVX.PA€56.30-3.43%3.6B-19.32-€2.95N/A
GLPG.AS€28.50+11.68%1.8B-6.21-€4.38N/A
ALNEV.PA€1.52-7.59%805M-0.01-€221.36N/A
GTBP.PA€280.50+0.00%626.7M-4.10-€68.39N/A
PHARM.AS€0.88+1.27%589.9M-43.05-€0.02N/A
MEDCL.PA€17.17+2.14%566M-15.70-€1.09N/A
Showing 1 to 10 of 69 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

ALVIO.PA vs UCB.BR Comparison July 2025

ALVIO.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALVIO.PA stands at 8.4M. In comparison, UCB.BR has a market cap of 33.9B. Regarding current trading prices, ALVIO.PA is priced at €0.06, while UCB.BR trades at €181.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALVIO.PA currently has a P/E ratio of -0.34, whereas UCB.BR's P/E ratio is 32.57. In terms of profitability, ALVIO.PA's ROE is -2.09%, compared to UCB.BR's ROE of +0.11%. Regarding short-term risk, ALVIO.PA is more volatile compared to UCB.BR. This indicates potentially higher risk in terms of short-term price fluctuations for ALVIO.PA.Check UCB.BR's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions

;